Literature DB >> 861146

Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses.

S Dische, M I Saunders, M E Lee, G E Adams, I R Flockhart.   

Abstract

The hypoxic cell radiosensitizer, Ro 07-0582, has now been given in multiple doses to 16 patients. They have received a total of 15-51 g in 3-20 doses. Immediate tolerance was good, and satisfactory plasma levels of the drug were consistently obtained. Neurotoxicity was, however, troublesome: convulsions occurred in the patient given the highest dose, and there was peripheral neuropathy in 11 cases. Tumour concentrations similar to those in plasma were obtained in human tumours, in contrast to the findings in mouse tumours where concentrations are usually below 40% of plasma levels. In the treatment of human tumours, a lower dose of Ro 07-0582 should give useful hypoxic cell sensitization. Although the total dose of Ro 07-0582 must be limited, there is a real prospect that it will give benefit in clinical radiotherapy.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 861146      PMCID: PMC2025511          DOI: 10.1038/bjc.1977.90

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  12 in total

Review 1.  The antibacterial activity of netronidazole.

Authors:  H R Ingham; J B Selkon; J H Hale
Journal:  J Antimicrob Chemother       Date:  1975-12       Impact factor: 5.790

2.  Clinical testing of the radiosensitiser Ro-07-0582. I. Dose tolerance, serum and tumour concentrations.

Authors:  A J Gray; S Dische; G E Adams; I R Flockhart; J L Foster
Journal:  Clin Radiol       Date:  1976-04       Impact factor: 2.350

3.  Radiotherapy using hyperbaric oxygen in the palliation of carcinoma of colon and rectum.

Authors:  S Dische; F Senanayake
Journal:  Clin Radiol       Date:  1972-10       Impact factor: 2.350

4.  Letter: An investigation of the pharmacological and radiosensitizing effects of the 2-nitroimidazole Ro-07-0582 in primates.

Authors:  R Johnson; C Gomer; J Ambrus; J Pearce; D Boyle
Journal:  Br J Radiol       Date:  1976-03       Impact factor: 3.039

5.  Radiation and high-dose metronidazole in supratentorial glioblastomas.

Authors:  R Urtasun; P Band; J D Chapman; M L Feldstein; B Mielke; C Fryer
Journal:  N Engl J Med       Date:  1976-06-17       Impact factor: 91.245

6.  Clinical testing of the radiosensitiser Ro-07-0582. III. Response of tumours.

Authors:  R H Thomlinson; S Dische; A J Gray; L M Errington
Journal:  Clin Radiol       Date:  1976-04       Impact factor: 2.350

7.  Electron-affinic sensitization. VII. A correlation between structures, one-electron reduction potentials, and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers.

Authors:  G E Adams; I R Flockhart; C E Smithen; I J Stratford; P Wardman; M E Watts
Journal:  Radiat Res       Date:  1976-07       Impact factor: 2.841

8.  Evaluation of rapid radiation treatment schedules utilizing two treatment sessions per day.

Authors:  C H Choi; H D Suit
Journal:  Radiology       Date:  1975-09       Impact factor: 11.105

9.  Clinical testing of the radiosensitiser Ro-07-0582. II. Radiosensitisation of normal and hypoxic skin.

Authors:  S Dische; A J Gray; G D Zanelli
Journal:  Clin Radiol       Date:  1976-04       Impact factor: 2.350

10.  Metronidazole neuropathy.

Authors:  A Coxon; C A Pallis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1976-04       Impact factor: 10.154

View more
  63 in total

1.  The neurotoxicity of misonidazole and its relationship to dose, half-life and concentration in the serum.

Authors:  M E Saunders; S Dische; P Anderson; I R Flockhart
Journal:  Br J Cancer Suppl       Date:  1978-06

2.  Further clinical experiences of a phase I study with the hypoxic cell radiosensitizer misonidazole.

Authors:  H D Kogelnik; J H Meyer; K Jentzsch; T Szepesi; K H Kärcher; E Maida; B Mamoli; P Wessely; F Zaunbauer
Journal:  Br J Cancer Suppl       Date:  1978-06

3.  Peripheral neuropathy related to misonidazole: incidence and pathology.

Authors:  R C Urtasun; J D Chapman; M L Feldstein; R P Band; H R Rabin; A F Wilson; B Marynowski; E Starreveld; T Shnitka
Journal:  Br J Cancer Suppl       Date:  1978-06

4.  The optimum regime for the administration of misonidazole and the establishment of multi-centre clinical trials.

Authors:  S Dische; M I Saunders; I R Flockhart
Journal:  Br J Cancer Suppl       Date:  1978-06

Review 5.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

6.  Six degrees of separation: the oxygen effect in the development of radiosensitizers.

Authors:  Bryan T Oronsky; Susan J Knox; Jan Scicinski
Journal:  Transl Oncol       Date:  2011-08-01       Impact factor: 4.243

7.  Some aspects of the metabolism of misonidazole.

Authors:  I R Flockhart; S L Malcolm; T R Marten; C S Parkins; R J Ruane; D Troup
Journal:  Br J Cancer Suppl       Date:  1978-06

8.  Evoked potentials in rats with misonidazole neurotoxicity. I. Brain stem auditory evoked potentials.

Authors:  M S Edwards; S K Powers; R A Baringer; D L Jewett; C Bolger; T L Phillips
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

9.  Plasma concentrations and pharmacokinetics of misonidazole after intraperitoneal administration to the mouse.

Authors:  M F Malmary-Nebot; C Labat; M Terrissol; B Martin; J Oustrin
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982 Jan-Mar       Impact factor: 2.441

10.  Structure-pharmacokinetic relationships for misonidazole analogues in mice.

Authors:  P Workman; J M Brown
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.